Brawn Biotech Intrinsic Value
Brawn Biotech (BRAWN) median intrinsic value is ₹26.67 from 5 valuation models (range ₹12–₹41), vs current price ₹22.20 — +20.1% upside (Trading Below Calculated Value), margin of safety 16.8%. For current market price and key ratios, visit BRAWN share price.
BRAWN Valuation Methods Summary — DCF, Graham Number & P/E
Brawn Biotech intrinsic value across 5 models vs current price ₹22.20 — upside/downside and value range per method. Read BRAWN ex-dividend dates for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹41.36 | ₹33.09 - ₹49.63 | +86.3% | EPS: ₹1.88, Sector P/E: 22x |
| Book Value Method | asset | ₹26.67 | ₹24.00 - ₹29.34 | +20.1% | Book Value/Share: ₹13.33, P/B: 2.0x |
| PEG Ratio Method | growth | ₹12.03 | ₹10.83 - ₹13.23 | -45.8% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹29.05 | ₹26.14 - ₹31.96 | +30.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹23.75 | ₹21.38 - ₹26.13 | +7.0% | EPS: ₹1.88, BVPS: ₹13.33 |
BRAWN Intrinsic Value vs Market Price — All Valuation Models
Brawn Biotech fair value range ₹12–₹41 vs current market price ₹22.20 across 5 valuation models. Analyse Brawn Biotech shareholding analysis to track promoter, FII and institutional holdings.
BRAWN Intrinsic Value Analysis — Undervalued or Overvalued?
Brawn Biotech median intrinsic value ₹26.67, current price ₹22.20 — Trading Below Calculated Value by 20.1%, margin of safety 16.8%.
What is the intrinsic value of BRAWN?
Based on our comprehensive analysis using 5 different valuation methods, the estimated intrinsic value of Brawn Biotech (BRAWN) is ₹26.67 (median value). With the current market price of ₹22.20, this represents a +20.1% variance from our estimated fair value.
The valuation range spans from ₹12.03 to ₹41.36, indicating ₹12.03 - ₹41.36.
Is BRAWN undervalued or overvalued?
Based on our multi-method analysis, Brawn Biotech (BRAWN) appears to be trading below calculated value by approximately 20.1%.
BRAWN Financial Health — Key Ratios vs Industry Benchmarks
Brawn Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 17.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Operating Margin | 25.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
BRAWN Cash Flow Quality — Operating & Free Cash Flow
Brawn Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |